Small-molecule drug conjugates for theranostics of prostate cancer

Conclusions:  In summary, we have successfully synthesized a small molecular conjugate, NO1A-DM1. Preliminary data from the proof-of-concept experiments with the conjugate convincingly support our rational design of the T-SMDC system for theranostics of prostate cancer. Acknowledgement This study was partially supported by a grant from the National Institutes of Health (R01 CA159144), a Synergistic Idea Award from the Department of Defense (W81XWH-12-1-0336), the Simmons Cancer Center Grant (NIH 5P30 CA 142543), the CPRIT Grant RP110771, and the Dr. Jack Krohmer Professorship Funds. The PC3-PIP and PC3-Flu cell lines were kindly provided by Dr. Martin G. Pomper from John Hopkins University.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: SPECIAL MTA: Preclinical Probes for Oncology Posters Source Type: research